$CBLL
Ceribell, Inc.

2024 Q4 Form 10-Q Financial Statement

#000095017024125409 Filed on November 12, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3 2024 Q2
Revenue $17.20M
YoY Change 48.09%
Cost Of Revenue $2.184M
YoY Change 15.86%
Gross Profit $15.01M
YoY Change 54.34%
Gross Profit Margin 87.3%
Selling, General & Admin $21.55M
YoY Change 47.81%
% of Gross Profit 143.58%
Research & Development $3.395M
YoY Change 47.1%
% of Gross Profit 22.62%
Depreciation & Amortization $79.00K $534.0K
YoY Change -12.22%
% of Gross Profit 0.53%
Operating Expenses $24.95M
YoY Change 47.71%
Operating Profit -$9.937M
YoY Change 38.71%
Interest Expense -$530.0K
YoY Change
% of Operating Profit
Other Income/Expense, Net $223.0K
YoY Change -65.43%
Pretax Income -$10.42M
YoY Change 47.68%
Income Tax
% Of Pretax Income
Net Earnings -$10.42M -$8.941M
YoY Change 47.68% 43.79%
Net Earnings / Revenue -60.58%
Basic Earnings Per Share -$1.85
Diluted Earnings Per Share -$1.85
COMMON SHARES
Basic Shares Outstanding 35.82M 5.635M
Diluted Shares Outstanding 5.635M

Balance Sheet

Concept 2024 Q4 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $14.11M $24.36M
YoY Change
Cash & Equivalents $14.10M $24.36M
Short-Term Investments
Other Short-Term Assets $2.266M $1.670M
YoY Change
Inventory $6.910M $5.757M
Prepaid Expenses
Receivables $9.973M $10.84M
Other Receivables $0.00 $0.00
Total Short-Term Assets $34.96M $42.62M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment $2.268M $4.774M
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $6.117M $4.515M
YoY Change
Total Long-Term Assets $12.10M $10.56M
YoY Change
TOTAL ASSETS
Total Short-Term Assets $34.96M $42.62M
Total Long-Term Assets $12.10M $10.56M
Total Assets $47.06M $53.18M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.776M $1.108M
YoY Change
Accrued Expenses $8.574M $8.188M
YoY Change
Deferred Revenue $105.0K
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change
Total Short-Term Liabilities $13.09M $10.46M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $19.50M $19.44M
YoY Change
Other Long-Term Liabilities $1.411M $3.146M
YoY Change
Total Long-Term Liabilities $22.54M $22.58M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $13.09M $10.46M
Total Long-Term Liabilities $22.54M $22.58M
Total Liabilities $35.63M $33.04M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$154.4M
YoY Change
Common Stock $18.39M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$136.0M -$127.3M
YoY Change
Total Liabilities & Shareholders Equity $47.06M $53.18M
YoY Change

Cashflow Statement

Concept 2024 Q4 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$10.42M -$8.941M
YoY Change 47.68% 43.79%
Depreciation, Depletion And Amortization $79.00K $534.0K
YoY Change -12.22%
Cash From Operating Activities -$8.542M -$16.53M
YoY Change
INVESTING ACTIVITIES
Capital Expenditures -$183.0K $1.288M
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $183.0K -$1.288M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.888M 7.676M
YoY Change
NET CHANGE
Cash From Operating Activities -8.542M -16.53M
Cash From Investing Activities 183.0K -1.288M
Cash From Financing Activities -1.888M 7.676M
Net Change In Cash -10.25M -10.14M
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$8.542M -$16.53M
Capital Expenditures -$183.0K $1.288M
Free Cash Flow -$8.359M -$17.81M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001861107
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-42364
dei Entity Registrant Name
EntityRegistrantName
CeriBell, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-1785452
dei Entity Address Address Line1
EntityAddressAddressLine1
360 N. Pastoria Avenue
dei Entity Address City Or Town
EntityAddressCityOrTown
Sunnyvale
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94085
dei City Area Code
CityAreaCode
800
dei Local Phone Number
LocalPhoneNumber
436-0826
dei Security12b Title
Security12bTitle
Common stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
CBLL
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
35824244
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14110000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
34495000
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
9973000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
7955000
CY2024Q3 us-gaap Inventory Net
InventoryNet
6910000
CY2023Q4 us-gaap Inventory Net
InventoryNet
5868000
CY2024Q3 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
1701000
CY2023Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
1515000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2266000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2130000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
34960000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
51963000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2268000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1577000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2365000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2160000
CY2024Q3 us-gaap Contract With Customer Asset Net Noncurrent
ContractWithCustomerAssetNetNoncurrent
1349000
CY2023Q4 us-gaap Contract With Customer Asset Net Noncurrent
ContractWithCustomerAssetNetNoncurrent
1238000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6117000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1984000
CY2024Q3 us-gaap Assets
Assets
47059000
CY2023Q4 us-gaap Assets
Assets
58922000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2776000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
732000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8574000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7540000
CY2024Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
105000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
206000
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
11833000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1029000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
694000
CY2024Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
605000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
595000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
13089000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
21600000
CY2024Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
19497000
CY2024Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
33000
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
44000
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1411000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
441000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1599000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1677000
CY2024Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
22540000
CY2023Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
2162000
CY2024Q3 us-gaap Liabilities
Liabilities
35629000
CY2023Q4 us-gaap Liabilities
Liabilities
23762000
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
76879683
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
76672748
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5779191
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5779191
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5430298
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5430298
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
6000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
5000
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
18380000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
14232000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-154368000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-126489000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-135982000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-112252000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
47059000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
58922000
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
17195000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11611000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
46910000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
32094000
CY2024Q3 us-gaap Cost Of Revenue
CostOfRevenue
2184000
CY2023Q3 us-gaap Cost Of Revenue
CostOfRevenue
1885000
us-gaap Cost Of Revenue
CostOfRevenue
6398000
us-gaap Cost Of Revenue
CostOfRevenue
5047000
CY2024Q3 us-gaap Gross Profit
GrossProfit
15011000
CY2023Q3 us-gaap Gross Profit
GrossProfit
9726000
us-gaap Gross Profit
GrossProfit
40512000
us-gaap Gross Profit
GrossProfit
27047000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3395000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2308000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9649000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6307000
CY2024Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
12524000
CY2023Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
9592000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
33812000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
28107000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9029000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4990000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
23876000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14293000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
24948000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
16890000
us-gaap Operating Expenses
OperatingExpenses
67337000
us-gaap Operating Expenses
OperatingExpenses
48707000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-9937000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-7164000
us-gaap Operating Income Loss
OperatingIncomeLoss
-26825000
us-gaap Operating Income Loss
OperatingIncomeLoss
-21660000
CY2024Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
530000
CY2023Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
532000
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
1493000
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
1585000
CY2024Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
173000
CY2023Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
3000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
417000
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
223000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
645000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
856000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2066000
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10417000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7054000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-27879000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-21179000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
11000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-10417000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-7054000
us-gaap Net Income Loss
NetIncomeLoss
-27879000
us-gaap Net Income Loss
NetIncomeLoss
-21190000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.85
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.85
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.32
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.32
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.02
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.02
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.02
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.02
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5634583
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5634583
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5343337
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5343337
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5549570
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5549570
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5274151
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5274151
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-112252000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
118000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
757000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-8521000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-119898000
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
488000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1076000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-8941000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-127275000
CY2024Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
334000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1376000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-10417000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-135982000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-86398000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
376000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
711000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-7918000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-93229000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
203000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
585000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-6218000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-98659000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
65000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
637000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-7054000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-105011000
us-gaap Profit Loss
ProfitLoss
-27879000
us-gaap Profit Loss
ProfitLoss
-21190000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
777000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
614000
cbll Noncash Lease Income Expense
NoncashLeaseIncomeExpense
-51000
cbll Noncash Lease Income Expense
NoncashLeaseIncomeExpense
11000
us-gaap Share Based Compensation
ShareBasedCompensation
3209000
us-gaap Share Based Compensation
ShareBasedCompensation
1933000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
289000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
273000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
417000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-82000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-152000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2018000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1581000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1041000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2076000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
137000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
681000
cbll Increase Decrease In Contract Costs
IncreaseDecreaseInContractCosts
298000
cbll Increase Decrease In Contract Costs
IncreaseDecreaseInContractCosts
725000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
65000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
22000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1153000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
848000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
504000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
85000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-112000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-103000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-25068000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22484000
cbll Payment Of Record Components And Recorders
PaymentOfRecordComponentsAndRecorders
122000
cbll Payment Of Record Components And Recorders
PaymentOfRecordComponentsAndRecorders
574000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
983000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
506000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1105000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1080000
cbll Proceeds From Exercise Of Common Stock Pursuant To Stock Option Exercises
ProceedsFromExerciseOfCommonStockPursuantToStockOptionExercises
940000
cbll Proceeds From Exercise Of Common Stock Pursuant To Stock Option Exercises
ProceedsFromExerciseOfCommonStockPursuantToStockOptionExercises
644000
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
7905000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
304000
us-gaap Payments For Repurchase Of Initial Public Offering
PaymentsForRepurchaseOfInitialPublicOffering
2753000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5788000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
644000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-20385000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-22920000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
34495000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
68235000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14110000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
45315000
us-gaap Interest Paid Net
InterestPaidNet
1194000
us-gaap Interest Paid Net
InterestPaidNet
1313000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
778000
cbll Property And Equipment Included In Accounts Payable And Accrued Expenses
PropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses
178000
cbll Property And Equipment Included In Accounts Payable And Accrued Expenses
PropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses
79000
cbll Recorder Components Included In Accounts Payable And Accrued Expenses
RecorderComponentsIncludedInAccountsPayableAndAccruedExpenses
61000
cbll Recorder Components Included In Accounts Payable And Accrued Expenses
RecorderComponentsIncludedInAccountsPayableAndAccruedExpenses
26000
cbll Unpaid Deferred Initial Public Offering Offering Costs Included In Accounts Payable And Accrued Liabilities
UnpaidDeferredInitialPublicOfferingOfferingCostsIncludedInAccountsPayableAndAccruedLiabilities
1142000
us-gaap Nature Of Operations
NatureOfOperations
<div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company</span></div></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Organization and Business</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CeriBell, Inc. (the “Company”) was incorporated in the state of Delaware as Brain Stethoscope, Inc., on August 29, 2014, and changed its name to CeriBell, Inc. on August 11, 2015, and maintains its principal office in Sunnyvale, California. The Company is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, highly portable and rapidly deployable hardware with sophisticated artificial intelligence (“AI”)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Initial Public Offering</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Immediately prior to the closing of the Company’s IPO on October 15, 2024, all shares of the Company’s redeemable convertible preferred stock converted into shares of the Company’s common stock.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On October 15, 2024, the Company completed its initial public offering of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12,196,969</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its common stock, which includes an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,590,909</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock purchased by the underwriters pursuant to their option to purchase additional shares, at a price to the public of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">17.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share. The gross proceeds to the Company from the initial public offering were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">207.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. The shares and proceeds from the Company’s IPO and the underwriters’ exercise of their option to purchase additional shares are not reflected in the condensed financial statements as of and for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three and nine months ended September 30, 2024. All of the outstanding shares of convertible preferred stock were converted into common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Liquidity</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of September 30, 2024 and December 31, 2023, the Company’s principal sources of liquidity consisted of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">14.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">34.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of cash and cash equivalents, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has incurred operating losses and negative cash flows from operations since its inception. On September 30, 2024 and December 31, 2023, the Company had an accumulated deficit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">154.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">126.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. Such losses primarily resulted from the costs incurred in the development and sales and marketing of the Company’s products and building the Company’s organization. The Company expects to incur losses in the near term as it continues to focus on the development and promotion of new and existing products and expand its corporate infrastructure, including the costs associated with being a public company.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 6, 2024, the Company entered into a Venture Loan and Security Agreement (“VLSA”) with Silicon Valley Bank, a division of First-Citizens Bank &amp; Trust Company (“SVB”), as a lender, and Horizon Technology Finance Corporation (“Horizon”), as a lender and the collateral agent. The VLSA provides a term loan commitment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Company drew $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million term loan commitment at closing, which was used to retire its existing debt with Horizon, pay transaction fees, and for general corporate purposes. The remaining $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">30.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million term loan commitment consists of three tranches of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million commitments, expiring on each of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2024</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The maturity date of VLSA is </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 1, 2029</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The VLSA is secured by all assets of the Company, excluding intellectual property. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There are no financial covenants as long as the net debt (defined as the difference between unrestricted cash and outstanding debt) does not exceed $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">40</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. Commencing on the last day of the calendar quarter in which the net debt exceeds $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">40.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and continuing until the repayment in full of the obligations (other than any inchoate indemnity obligations), the Company covenants, as of the last day of each fiscal quarter, to achieve annualized trailing six month revenue in an amount equal to or no less than its net debt balance. The Company must also maintain account balances in accounts at or through SVB representing at least fifty percent (50%) of the value of all deposit account balances all financial institutions through the time at which the debt has been repaid in full.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Additionally, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the Company shall obtain any business credit card, letter of credit and cash management services exclusively from SVB. In the event that the Company breaches one or more covenants, each lender’s obligation to lend its undisbursed portion of the loan commitment shall terminate and the lenders may choose</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">declare an event of default and require that the Company immediately repay all amounts outstanding of the aggregate principal amount, plus accrued interest, and foreclose on the collateral granted to it to secure such indebtedness.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Concurrent with the VLSA, the Company executed a Loan and Security Agreement with SVB to receive a senior revolving line of credit of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (“Revolving Facility”). The Revolving Facility is secured by the Company's accounts receivable, inventory, and other property. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There are no financial covenants as long as the net debt (defined as the difference between unrestricted cash and outstanding debt) does not exceed $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">40</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. Commencing on the last day of the calendar quarter in which the net debt exceeds $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">40.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and continuing until the repayment in full of the obligations, the Company covenants, as of the last day of each fiscal quarter, to achieve a recurring revenue ratio of not less than 1.00:1.00. The recurring revenue ratio is defined as annualized trailing six months of revenue divided by net debt.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The Company may draw amounts up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">85</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the eligible trade receivables. In the event that the Company breaches one or more covenants, the lender may choose to declare an event of default and require that the Company immediately repay all obligations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On October 15, 2024, the Company completed its initial public offering and received gross proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">207.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on the Company’s current operating plan, the Company believes that its existing cash and cash equivalents will be sufficient to fund the Company’s planned operating expenses and capital expenditure requirements for at least the next 12 months from the date these financial statements were available to be issued.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">However, the Company may experience lower than expected cash generated from operating activities or greater than expected capital expenditures, cost of revenue, or operating expenses, and may need to raise additional capital to fund operations, further research and development activities, or acquire, invest in, or license other businesses, assets, or technologies. The Company’s future capital needs will depend upon many factors, including the market acceptance of the Company’s products, the cost and pace of developing new products, and the costs of supporting sales growth.</span></p>
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14100000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
34500000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-154400000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-126500000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates and assumptions, and such differences could be material to the Company’s financial position and results of operations. Significant estimates and assumptions include, but are not limited to, valuation of warrants, valuation of the Company’s common stock (prior to the IPO), and valuation of the Company’s options to purchase common stock for purposes of accounting for stock-based compensation.</span></p>
CY2024Q3 cbll Operating Lease Term
OperatingLeaseTerm
P1Y
CY2024Q3 cbll Percentage Of Voting Power Entity
PercentageOfVotingPowerEntity
0.50
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. The Company’s cash and cash equivalents are invested in checking accounts and money market funds. The Company has not experienced any losses to date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company’s accounts receivables are derived solely from product and subscription sales to customers located in the United States. The Company performs periodic evaluations of its customers’ financial condition and generally requires no collateral from its customers. Credit losses historically have not been significant. No customers comprised 10% of the Company revenue for the three and nine months ended September 30, 2024 or 2023. No customers comprised 10% of the Company's accounts receivable balance as of September 30, 2024 or December 31, 2023.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Bank failures, events involving limited liquidity, defaults, non-performance, or other adverse developments that affect financial institutions, or concerns or rumors about such events, may lead to liquidity constraints. The failure of a bank, or other adverse conditions in the financial or credit markets impacting financial institutions at which the Company maintains balances, could adversely impact liquidity and financial performance. There can be no assurance that the Company’s deposits in excess of the Federal Deposit Insurance Corporation (“FDIC”) or other comparable insurance limits will be backstopped by the U.S. or applicable foreign governments, or that any bank or financial institution with which the Company does business will be able to obtain needed liquidity from other banks, government institutions, or by acquisition in the event of a failure or liquidity crisis. The Company’s cash and cash equivalents are primarily held in money market funds.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2023Q4 us-gaap Deferred Costs
DeferredCosts
0
CY2024Q3 us-gaap Deferred Costs
DeferredCosts
3900000
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2024Q3 us-gaap Advertising Expense
AdvertisingExpense
108000
CY2023Q3 us-gaap Advertising Expense
AdvertisingExpense
272000
us-gaap Advertising Expense
AdvertisingExpense
271000
us-gaap Advertising Expense
AdvertisingExpense
384000
us-gaap Revenue Performance Obligation Description Of Payment Terms
RevenuePerformanceObligationDescriptionOfPaymentTerms
The Company accounts for a contract when both parties have approved the contract and the Company is committed to perform its obligations, the rights of the parties are identified, payment terms (generally net 30 days) are identified, the contract has commercial substance, and collectability of consideration is probable.
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
17195000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11611000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
46910000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
32094000
CY2024Q2 us-gaap Capitalized Contract Cost Net
CapitalizedContractCostNet
2890000
CY2023Q2 us-gaap Capitalized Contract Cost Net
CapitalizedContractCostNet
2558000
CY2023Q4 us-gaap Capitalized Contract Cost Net
CapitalizedContractCostNet
2753000
CY2022Q4 us-gaap Capitalized Contract Cost Net
CapitalizedContractCostNet
1981000
CY2024Q3 cbll Capitalized Contract Costs Capitalized During The Period
CapitalizedContractCostsCapitalizedDuringThePeriod
681000
CY2023Q3 cbll Capitalized Contract Costs Capitalized During The Period
CapitalizedContractCostsCapitalizedDuringThePeriod
569000
cbll Capitalized Contract Costs Capitalized During The Period
CapitalizedContractCostsCapitalizedDuringThePeriod
1744000
cbll Capitalized Contract Costs Capitalized During The Period
CapitalizedContractCostsCapitalizedDuringThePeriod
1820000
CY2024Q3 us-gaap Capitalized Contract Cost Amortization
CapitalizedContractCostAmortization
521000
CY2023Q3 us-gaap Capitalized Contract Cost Amortization
CapitalizedContractCostAmortization
422000
us-gaap Capitalized Contract Cost Amortization
CapitalizedContractCostAmortization
1447000
us-gaap Capitalized Contract Cost Amortization
CapitalizedContractCostAmortization
1096000
CY2024Q3 us-gaap Capitalized Contract Cost Net
CapitalizedContractCostNet
3050000
CY2023Q3 us-gaap Capitalized Contract Cost Net
CapitalizedContractCostNet
2705000
CY2024Q3 us-gaap Capitalized Contract Cost Net
CapitalizedContractCostNet
3050000
CY2023Q3 us-gaap Capitalized Contract Cost Net
CapitalizedContractCostNet
2705000
CY2024Q3 cbll Contract With Customer Liability Related To Up Front Payments
ContractWithCustomerLiabilityRelatedToUpFrontPayments
138000
CY2023Q3 cbll Contract With Customer Liability Related To Up Front Payments
ContractWithCustomerLiabilityRelatedToUpFrontPayments
240000
CY2024Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
349000
CY2023Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
334000
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
250000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
343000
CY2024Q3 cbll Contract With Customer Liability Revenue Additional
ContractWithCustomerLiabilityRevenueAdditional
90000
CY2023Q3 cbll Contract With Customer Liability Revenue Additional
ContractWithCustomerLiabilityRevenueAdditional
265000
cbll Contract With Customer Liability Revenue Additional
ContractWithCustomerLiabilityRevenueAdditional
704000
cbll Contract With Customer Liability Revenue Additional
ContractWithCustomerLiabilityRevenueAdditional
623000
CY2024Q3 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
-301000
CY2023Q3 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
-359000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
-816000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
-726000
CY2024Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
138000
CY2023Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
240000
CY2024Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
138000
CY2023Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
240000
CY2024Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
0
CY2023Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
33831000
CY2023Q4 cbll Warrant Liability Fair Value Disclosure
WarrantLiabilityFairValueDisclosure
334000
CY2023Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
334000
CY2024Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
13588000
CY2024Q3 cbll Warrant Liability Fair Value Disclosure
WarrantLiabilityFairValueDisclosure
1055000
CY2024Q3 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
1055000
CY2024Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
3991000
CY2023Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
3405000
CY2024Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
2919000
CY2023Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
2463000
CY2024Q3 us-gaap Inventory Net
InventoryNet
6910000
CY2023Q4 us-gaap Inventory Net
InventoryNet
5868000
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3994000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2945000
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1726000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1368000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2268000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1577000
CY2024Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
164000
CY2023Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
173000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
482000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
373000
CY2024Q3 cbll Recorders At Customer Locations Gross
RecordersAtCustomerLocationsGross
1181000
CY2023Q4 cbll Recorders At Customer Locations Gross
RecordersAtCustomerLocationsGross
969000
CY2024Q3 cbll Accumulated Depreciation Of Recorders At Customer Locations
AccumulatedDepreciationOfRecordersAtCustomerLocations
712000
CY2023Q4 cbll Accumulated Depreciation Of Recorders At Customer Locations
AccumulatedDepreciationOfRecordersAtCustomerLocations
484000
CY2024Q3 cbll Recorders At Customer Locations Net
RecordersAtCustomerLocationsNet
469000
CY2023Q4 cbll Recorders At Customer Locations Net
RecordersAtCustomerLocationsNet
485000
CY2024Q3 cbll Recorders And Related Components
RecordersAndRelatedComponents
1158000
CY2023Q4 cbll Recorders And Related Components
RecordersAndRelatedComponents
1347000
CY2024Q3 us-gaap Deferred Costs
DeferredCosts
3895000
CY2024Q3 us-gaap Deferred Finance Costs Noncurrent Gross
DeferredFinanceCostsNoncurrentGross
378000
CY2024Q3 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
217000
CY2023Q4 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
152000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6117000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1984000
CY2024Q3 us-gaap Depreciation
Depreciation
79000
CY2023Q3 us-gaap Depreciation
Depreciation
90000
us-gaap Depreciation
Depreciation
295000
us-gaap Depreciation
Depreciation
241000
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2925000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3132000
CY2024Q3 us-gaap Accrued Sales Commission Current
AccruedSalesCommissionCurrent
2509000
CY2023Q4 us-gaap Accrued Sales Commission Current
AccruedSalesCommissionCurrent
2190000
CY2024Q3 cbll Accrued Professional Fees And Other Costs Current
AccruedProfessionalFeesAndOtherCostsCurrent
3046000
CY2023Q4 cbll Accrued Professional Fees And Other Costs Current
AccruedProfessionalFeesAndOtherCostsCurrent
2106000
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
94000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
112000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8574000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7540000
us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Amount
DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
0
CY2023 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Amount
DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
0
CY2023Q4 us-gaap Litigation Reserve
LitigationReserve
0
CY2024Q3 us-gaap Litigation Reserve
LitigationReserve
0
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2365000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2160000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1029000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
694000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1599000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1677000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
2628000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2371000
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y3M18D
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y1M6D
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0717
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0625
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
269000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1216000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1255000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
107000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2847000
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
219000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
2628000
CY2024Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
297000
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
196000
us-gaap Operating Lease Expense
OperatingLeaseExpense
730000
us-gaap Operating Lease Expense
OperatingLeaseExpense
625000
CY2024Q3 us-gaap Operating Lease Variable Lease Income
OperatingLeaseVariableLeaseIncome
52000
CY2023Q3 us-gaap Operating Lease Variable Lease Income
OperatingLeaseVariableLeaseIncome
44000
us-gaap Operating Lease Variable Lease Income
OperatingLeaseVariableLeaseIncome
216000
us-gaap Operating Lease Variable Lease Income
OperatingLeaseVariableLeaseIncome
211000
CY2024Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
245000
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
152000
us-gaap Operating Lease Cost
OperatingLeaseCost
514000
us-gaap Operating Lease Cost
OperatingLeaseCost
414000
CY2024Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
204000
CY2023Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
198000
us-gaap Operating Lease Payments
OperatingLeasePayments
641000
us-gaap Operating Lease Payments
OperatingLeasePayments
593000
CY2024Q1 cbll Percentage Of Trade Receivable
PercentageOfTradeReceivable
0.85
CY2024Q1 cbll Line Of Credit Facility Interest Rate At Prime Rate
LineOfCreditFacilityInterestRateAtPrimeRate
0.0025
CY2024Q1 cbll Line Of Credit Facility Interest Rate Floor
LineOfCreditFacilityInterestRateFloor
0.06
CY2024Q1 cbll Line Of Credit Facility Additional Fees
LineOfCreditFacilityAdditionalFees
300000
CY2024Q1 us-gaap Line Of Credit Facility Expiration Date1
LineOfCreditFacilityExpirationDate1
2026-02-06
CY2024Q1 cbll Term Loan Liability
TermLoanLiability
535000
CY2024Q1 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
347000
CY2024Q1 cbll Revolving Facility Debt Financing Cost
RevolvingFacilityDebtFinancingCost
116000
CY2024Q1 us-gaap Debt Instrument Term
DebtInstrumentTerm
P2Y
CY2024Q3 us-gaap Line Of Credit Facility Interest Rate At Period End
LineOfCreditFacilityInterestRateAtPeriodEnd
0.095
CY2024Q1 cbll Line Of Credit Facility Interest Rate On Term Loan And Revolving Facility
LineOfCreditFacilityInterestRateOnTermLoanAndRevolvingFacility
0.05
CY2024Q1 cbll Percentage Of Late Payment Fee
PercentageOfLatePaymentFee
0.06
CY2024Q3 us-gaap Line Of Credit Facility Remaining Borrowing Capacity
LineOfCreditFacilityRemainingBorrowingCapacity
0
CY2024Q3 cbll Principal Of Notes Payable
PrincipalOfNotesPayable
20000000
CY2023Q4 cbll Principal Of Notes Payable
PrincipalOfNotesPayable
11250000
CY2024Q3 cbll End Of Term Fee Accretion
EndOfTermFeeAccretion
81000
CY2023Q4 cbll End Of Term Fee Accretion
EndOfTermFeeAccretion
647000
CY2024Q3 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
584000
CY2023Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
64000
CY2024Q3 us-gaap Notes Payable
NotesPayable
19497000
CY2023Q4 us-gaap Notes Payable
NotesPayable
11833000
CY2024Q3 us-gaap Preferred Stock Convertible Conversion Ratio
PreferredStockConvertibleConversionRatio
1
CY2023Q4 us-gaap Preferred Stock Convertible Conversion Ratio
PreferredStockConvertibleConversionRatio
1
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
60954
cbll Warrants Issued
WarrantsIssued
41345
CY2024Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
102299
CY2024Q1 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
60000000
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
76879683
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
76672748
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2023 us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2024Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
23753112
CY2023Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
23034141
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4746527
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.04
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y2M1D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
13383000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1713753
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
11.68
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
348943
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.69
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
434439
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
5.12
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5676898
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.35
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y10M28D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
59386000
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
5676898
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
6.35
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y10M28D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
59386000
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2555661
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.76
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y9M
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
33358000
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y6M
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y1M6D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y4M24D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.634
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.745
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.683
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.756
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.038
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.045
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.041
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.041
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1376000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
637000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3209000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1933000
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1200000
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
700000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
2800000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1800000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-10417000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-7054000
us-gaap Net Income Loss
NetIncomeLoss
-27879000
us-gaap Net Income Loss
NetIncomeLoss
-21190000
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5635000
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5635000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5343000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5343000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5550000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5550000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5274000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5274000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.85
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.85
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.32
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.32
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.02
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.02
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.02
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.02
CY2024Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
23597000
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
22533000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
23597000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
22533000
CY2024Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2023Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-125409-index-headers.html Edgar Link pending
0000950170-24-125409-index.html Edgar Link pending
0000950170-24-125409.txt Edgar Link pending
0000950170-24-125409-xbrl.zip Edgar Link pending
cbll-20240930.htm Edgar Link pending
cbll-20240930.xsd Edgar Link pending
cbll-ex31_1.htm Edgar Link pending
cbll-ex31_2.htm Edgar Link pending
cbll-ex32_1.htm Edgar Link pending
cbll-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
cbll-20240930_htm.xml Edgar Link completed
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending